Skip to main content
SpringerLink
Log in

Circulating Tumor Cells in Breast Cancer Metastatic Disease

  • Book
  • © 2020

Overview

Editors:
  1. Roberto Piñeiro

    1. Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet) Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • This book is useful for anyone interested in the fast growing field of circulating tumor cells (CTCs)
  • Readers will discover the fundamental knowledge about the role of CTCs in breast cancer provided by experts in the field
  • This volume provides up-to-date information on the use of CTCs as a biomarker for the management of breast cancer patients

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1220)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (10 chapters)

  1. Front Matter

    Pages i-xv
    Download chapter PDF

  2. Introduction – Biology of Breast Cancer Metastasis and Importance of the Analysis of CTCs

    • Roberto Piñeiro
    Pages 1-10

  3. Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis

    • Risa Burr, Christine Gilles, Erik W. Thompson, Shyamala Maheswaran
    Pages 11-34

  4. Disseminated Tumor Cells and Dormancy in Breast Cancer Progression

    • Malgorzata Banys-Paluchowski, Florian Reinhardt, Tanja Fehm
    Pages 35-43

  5. Methodology for the Isolation and Analysis of CTCs

    • Clotilde Costa, Ana B. Dávila-Ibáñez
    Pages 45-59

  6. Advances in the Characterization of Circulating Tumor Cells in Metastatic Breast Cancer: Single Cell Analyses and Interactions, and Patient-Derived Models for Drug Testing

    • Praveen K. Kujur, Bianca C. T. Flores, Naveen Ramalingam, Ludmilla T. D. Chinen, Stefanie S. Jeffrey
    Pages 61-80

  7. Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs

    • Marta Vismara, Carolina Reduzzi, Maria Grazia Daidone, Vera Cappelletti
    Pages 81-91

  8. Relevance of CTC Clusters in Breast Cancer Metastasis

    • Roberto Piñeiro, Inés Martínez-Pena, Rafael López-López
    Pages 93-115

  9. Epigenetics of Circulating Tumor Cells in Breast Cancer

    • Aida Bao-Caamano, Aitor Rodriguez-Casanova, Angel Diaz-Lagares
    Pages 117-134

  10. Circulating Tumor Cells: Applications for Early Breast Cancer

    • Tamara Martos, David Casadevall, Joan Albanell
    Pages 135-146

  11. Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer

    • Juan F. Cueva Bañuelos, Carmela Rodríguez López, Alexandra Cortegoso Mosquera, Patricia Palacios Ozores, Teresa Curiel García
    Pages 147-164

  12. Back Matter

    Pages 165-167
    Download chapter PDF
Back to top

Keywords

About this book

This book is aimed to summarise the key aspects of the role of circulating tumour cells (CTCs) in breast cancer, with special attention to their contribution to tumour progression and establishment of metastatic disease. We aim to give a clear overview of the knowledge about CTCs, framed in the context of breast cancer, by analysing basic and clinical research carried out so far. In a broader sense, we will address what are the main clinical needs of this disease based on its molecular heterogeneity (subtypes) and lay out the knowledge and understanding that CTCs are giving about it and how they are contributing and can still improve the better monitoring and management of breast cancer patients. We will discuss the evidences of the use of CTCs as a tool to monitor cancer progression and therapy response, based on the prognostic and predictive value they have, as well as a tool to unravel mechanisms of resistance to therapy and to identify new biomarkers allowing to predict therapy success. Moreover, we will analyse the main aspects of ongoing clinical trials and how they can contribute to determine the clinical utility of CTCs as a breast cancer biomarker. We will also touch upon general knowledge or basic notions of the biology of the metastatic process in epithelial cancers, in order to understand the origin and biology of CTCs. In this sense, we will pay special attention to EMT (epithelial to mesenchymal transition), dormancy and minimal residual disease, three key aspects that determine the outcome of the disease. We will also cover general aspects on the isolation and characterization techniques applies to the study of CTCs, and also the possibilities that the study of CTCs, as a biomarker with biological function, is opening in terms of understanding the biology of metastatic cells and the identification of therapeutic targets based on the functional and molecular characterization of CTCs. Lastly, we will try to foresee the future of CTCs in terms of clinical application and implementation in the clinical routine.

Editors and Affiliations

  • Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet) Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain

    Roberto Piñeiro

About the editor

Roberto Piñeiro completed his doctoral studies on the biology and metabolism of cardiomyocytes in 2005, in the Department of Medicine at the University of Santiago de Compostela. In 2007 he joined the Phosphoinositide group for his post-doctoral in the Blizard Institute, Queen Mary University of London, where he studied the role of the GPR55 receptor and its ligand, lysophosphatidyl inositol (LPI) on cell proliferation in prostate and ovarian cancer.

Then in 2011 he was incorporated into the Cell Signalling group of Barts Cancer Institute, Queen Mary University of London, currently located at the UCL Cancer Institute, University College London. In this laboratory, Roberto worked studying the role of Class I PI3K in cell signalling in cancer and the tumour micro environment using “knock-in” mice and cellular models.

He is currently Head of the Cancer Modelling Line of the Roche-Chus Joint Unit

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation